GlassScriptPhysician profile
Roger Alan Rodby
NPI 1043327927
$26,652.05
in general payments reported to CMS, 2019-2025
22 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $7,000 · 2021: $1,567 · 2022: $2,542 · 2023: $8,177 · 2024: $5,395 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,500 · Food and Beverage: $3,711 · Travel and Lodging: $2,061 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,500.00 |
| Food and Beverage | $3,711.09 |
| Travel and Lodging | $2,060.58 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $14,664.87 | 2019-2023 | Nxstage System One |
| Fresenius USA Marketing, INC. | $9,927.28 | 2023-2024 | Nxstage System One |
| Amgen INC. | $465.87 | 2023-2025 | Tavneos, Aranesp, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $255.26 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $170.10 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $148.29 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $138.11 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.35 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.47 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $91.37 | 2023-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $74.24 | 2021-2025 | Voyxact |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $68.46 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $57.83 | 2023-2024 | Acthar |
| Vifor Pharma, INC. | $52.81 | 2025 | Veltassa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $40.82 | 2024 | Renal - Amia |
| Glaxosmithkline, LLC. | $39.14 | 2024 | Jesduvroq |
| Merck Sharp & Dohme LLC | $28.35 | 2025 | Prevymis |
| Vantive US Healthcare LLC | $26.66 | 2025 | Renal - Pd |
| Chiesi USA, INC. | $23.32 | 2025 | Elfabrio |
| Ardelyx, INC. | $22.93 | 2024 | Ibsrela |
| Medtronic, INC. | $21.52 | 2023 | Ellipsys Vascular Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Rodby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.